{"id":893152,"date":"2025-10-07T08:04:35","date_gmt":"2025-10-07T12:04:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\/"},"modified":"2025-10-07T08:04:35","modified_gmt":"2025-10-07T12:04:35","slug":"bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\/","title":{"rendered":"bioAffinity Technologies Reports Record Growth in CyPath\u00ae Lung Test Volume for Third Quarter 2025"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>bioAffinity Technologies Reports Record Growth in CyPath<sup>\u00ae<\/sup> Lung Test Volume for Third Quarter 2025<\/b><\/p>\n<p>SAN ANTONIO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bioaffinitytech.com&amp;esheet=54335005&amp;newsitemid=20251007557170&amp;lan=en-US&amp;anchor=bioAffinity+Technologies%2C+Inc.&amp;index=1&amp;md5=8ccfd231d46848346b148c345c0de8bf\"><b>bioAffinity Technologies, Inc.<\/b><\/a><b> (Nasdaq: BIAF; BIAFW)<\/b>,<b \/>a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced sales of its CyPath<sup>\u00ae<\/sup> Lung diagnostic test for lung cancer reached a new high in the third quarter of 2025, representing a 95% increase over the previous quarter. The increase reflects growing adoption by Veterans\u2019 hospitals and market expansion in the mid-Atlantic region. In the first nine months of 2025, sales of CyPath<sup>\u00ae<\/sup> Lung rose 97% over the same period in 2024.<\/p>\n<p>\n\u201cThe continued acceleration in CyPath<sup>\u00ae<\/sup> Lung adoption underscores the growing physician confidence in our test to detect lung cancer at its earliest, most treatable stages,\u201d said Maria Zannes, President and CEO of bioAffinity Technologies. \u201cPhysicians are equally impressed by CyPath<sup>\u00ae<\/sup> Lung\u2019s ability to save patients from unnecessary invasive procedures when the nodule is benign.&#8221;<\/p>\n<p>\n\u201cOur strong quarter-over-quarter growth demonstrates that CyPath<sup>\u00ae<\/sup> Lung is gaining traction in the marketplace, and we are encouraged by the test\u2019s increasing integration into clinical practice,\u201d Zannes said. \u201cPerformance metrics showed similar improvements in the third quarter, including a 77% increase in the number of new patients using CyPath<sup>\u00ae<\/sup> Lung and greater patient compliance for at-home sample collection and return.\u201d<\/p>\n<p>\nPublished patient case studies demonstrate the clinical impact of CyPath<sup>\u00ae<\/sup> Lung, including:<\/p>\n<ul class=\"bwlistdisc\">\n<li><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cypathlung.com%2Fwp-content%2Fuploads%2F2025%2F08%2FCyPath_case-study_Mary_Stage-1A.pdf&amp;esheet=54335005&amp;newsitemid=20251007557170&amp;lan=en-US&amp;anchor=Detecting+Stage+1A+lung+cancer&amp;index=2&amp;md5=da6b07c248d5868c7d8146d897b0f103\"><b>Detecting Stage 1A lung cancer<\/b><\/a> in patients after other diagnostics suggested a low probability of cancer.\n<\/li>\n<li><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cypathlung.com%2Fwp-content%2Fuploads%2F2025%2F08%2FBIO25_1012_R6_CP-25011-CyPath-Lung-Case-Study-Leavebehind_JAMES.pdf&amp;esheet=54335005&amp;newsitemid=20251007557170&amp;lan=en-US&amp;anchor=Sparing+patients+from+invasive+procedures&amp;index=3&amp;md5=92f25985541270fe1474e98ca452095b\"><b>Sparing patients from invasive procedures<\/b><\/a> when the CyPath<sup>\u00ae<\/sup> Lung result was negative.\n<\/li>\n<li>\nDetecting lung cancer earlier in<b><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cypathlung.com%2Fwp-content%2Fuploads%2F2025%2F10%2FCyPath_case-study_Helen_ground-glass_FINAL.pdf&amp;esheet=54335005&amp;newsitemid=20251007557170&amp;lan=en-US&amp;anchor=difficult-to-diagnose+ground-glass+nodules&amp;index=4&amp;md5=7c4661dc42f13b5e5a9227d95acfe62d\">difficult-to-diagnose ground-glass nodules<\/a>.<\/b><\/li>\n<\/ul>\n<p>\n\u201cAs we expand our marketing and sales efforts, we are immensely proud of the real-world impact CyPath<sup>\u00ae<\/sup> Lung is having on patients and their families,\u201d said Gordon Downie, MD, PhD, Chief Medical Officer of bioAffinity Technologies. \u201cEvery early cancer detected means a life that may be saved, and every unnecessary invasive procedure avoided means a patient spared from risk, anxiety and cost. This is why more physicians are adding CyPath<sup>\u00ae<\/sup> Lung as an essential tool in the diagnostic pathway.\u201d<\/p>\n<p><b>About CyPath<sup>\u00ae<\/sup> Lung<\/b><\/p>\n<p>\nCyPath<sup>\u00ae<\/sup> Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath<sup>\u00ae<\/sup> Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Frespiratory-research.biomedcentral.com%2Farticles%2F10.1186%2Fs12931-023-02327-3&amp;esheet=54335005&amp;newsitemid=20251007557170&amp;lan=en-US&amp;anchor=Clinical+study+results&amp;index=5&amp;md5=c5fc38c31d05b421fb4c1257ee573557\">Clinical study results<\/a> demonstrated that CyPath<sup>\u00ae<\/sup> Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cypathlung.com&amp;esheet=54335005&amp;newsitemid=20251007557170&amp;lan=en-US&amp;anchor=www.cypathlung.com&amp;index=6&amp;md5=4eab795314292f4426a606310056bfcc\">www.cypathlung.com<\/a>.<\/p>\n<p><b>About bioAffinity Technologies, Inc.<\/b><\/p>\n<p>\nbioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company\u2019s first product, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cypathlung.com%2F&amp;esheet=54335005&amp;newsitemid=20251007557170&amp;lan=en-US&amp;anchor=CyPath%26%23174%3B+Lung&amp;index=7&amp;md5=b3f8481b6ab6bf61eae567c7eda3e1bf\">CyPath<sup>\u00ae<\/sup> Lung<\/a>, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath<sup>\u00ae<\/sup> Lung is marketed as a Laboratory Developed Test (LDT) by <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.precisionpath.us%2F&amp;esheet=54335005&amp;newsitemid=20251007557170&amp;lan=en-US&amp;anchor=Precision+Pathology+Laboratory+Services&amp;index=8&amp;md5=1e0ed262cc401f007a81442e894fe444\">Precision Pathology Laboratory Services<\/a>, a subsidiary of bioAffinity Technologies. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fbioaffinitytech.com%2F&amp;esheet=54335005&amp;newsitemid=20251007557170&amp;lan=en-US&amp;anchor=www.bioaffinitytech.com&amp;index=9&amp;md5=f67fbd5f3edad44d5a9cf95f249f985a\">www.bioaffinitytech.com<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nCertain statements in this press release constitute &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws. Words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;predict,&#8221; &#8220;forecast,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;intend&#8221; or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company\u2019s ability to continue sales growth in 2025 and beyond, and the other factors discussed in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251007557170r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20251007557170\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20251007557170\/en\/<\/a><\/span><\/p>\n<p><b>bioAffinity Technologies<br \/>\n<\/b><br \/>Julie Anne Overton<br \/>\n<br \/>Director of Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jao@bioaffinitytech.com\">jao@bioaffinitytech.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Texas United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Other Health Radiology Pharmaceutical Oncology Medical Devices Genetics Surgery Clinical Trials Science Biotechnology Health Other Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251007557170\/en\/797432\/3\/bioAfinity_logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>bioAffinity Technologies Reports Record Growth in CyPath\u00ae Lung Test Volume for Third Quarter 2025 SAN ANTONIO&#8211;(BUSINESS WIRE)&#8211;bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced sales of its CyPath\u00ae Lung diagnostic test for lung cancer reached a new high in the third quarter of 2025, representing a 95% increase over the previous quarter. The increase reflects growing adoption by Veterans\u2019 hospitals and market expansion in the mid-Atlantic region. In the first nine months of 2025, sales of CyPath\u00ae Lung rose 97% over the same period in 2024. \u201cThe continued acceleration in CyPath\u00ae Lung adoption underscores the growing physician confidence in our test to detect lung cancer at its earliest, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;bioAffinity Technologies Reports Record Growth in CyPath\u00ae Lung Test Volume for Third Quarter 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-893152","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>bioAffinity Technologies Reports Record Growth in CyPath\u00ae Lung Test Volume for Third Quarter 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"bioAffinity Technologies Reports Record Growth in CyPath\u00ae Lung Test Volume for Third Quarter 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"bioAffinity Technologies Reports Record Growth in CyPath\u00ae Lung Test Volume for Third Quarter 2025 SAN ANTONIO&#8211;(BUSINESS WIRE)&#8211;bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced sales of its CyPath\u00ae Lung diagnostic test for lung cancer reached a new high in the third quarter of 2025, representing a 95% increase over the previous quarter. The increase reflects growing adoption by Veterans\u2019 hospitals and market expansion in the mid-Atlantic region. In the first nine months of 2025, sales of CyPath\u00ae Lung rose 97% over the same period in 2024. \u201cThe continued acceleration in CyPath\u00ae Lung adoption underscores the growing physician confidence in our test to detect lung cancer at its earliest, &hellip; Continue reading &quot;bioAffinity Technologies Reports Record Growth in CyPath\u00ae Lung Test Volume for Third Quarter 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-07T12:04:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251007557170r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"bioAffinity Technologies Reports Record Growth in CyPath\u00ae Lung Test Volume for Third Quarter 2025\",\"datePublished\":\"2025-10-07T12:04:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\\\/\"},\"wordCount\":837,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251007557170r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\\\/\",\"name\":\"bioAffinity Technologies Reports Record Growth in CyPath\u00ae Lung Test Volume for Third Quarter 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251007557170r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-10-07T12:04:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251007557170r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251007557170r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"bioAffinity Technologies Reports Record Growth in CyPath\u00ae Lung Test Volume for Third Quarter 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"bioAffinity Technologies Reports Record Growth in CyPath\u00ae Lung Test Volume for Third Quarter 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\/","og_locale":"en_US","og_type":"article","og_title":"bioAffinity Technologies Reports Record Growth in CyPath\u00ae Lung Test Volume for Third Quarter 2025 - Market Newsdesk","og_description":"bioAffinity Technologies Reports Record Growth in CyPath\u00ae Lung Test Volume for Third Quarter 2025 SAN ANTONIO&#8211;(BUSINESS WIRE)&#8211;bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced sales of its CyPath\u00ae Lung diagnostic test for lung cancer reached a new high in the third quarter of 2025, representing a 95% increase over the previous quarter. The increase reflects growing adoption by Veterans\u2019 hospitals and market expansion in the mid-Atlantic region. In the first nine months of 2025, sales of CyPath\u00ae Lung rose 97% over the same period in 2024. \u201cThe continued acceleration in CyPath\u00ae Lung adoption underscores the growing physician confidence in our test to detect lung cancer at its earliest, &hellip; Continue reading \"bioAffinity Technologies Reports Record Growth in CyPath\u00ae Lung Test Volume for Third Quarter 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-07T12:04:35+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251007557170r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"bioAffinity Technologies Reports Record Growth in CyPath\u00ae Lung Test Volume for Third Quarter 2025","datePublished":"2025-10-07T12:04:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\/"},"wordCount":837,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251007557170r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\/","name":"bioAffinity Technologies Reports Record Growth in CyPath\u00ae Lung Test Volume for Third Quarter 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251007557170r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-10-07T12:04:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251007557170r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251007557170r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-record-growth-in-cypath-lung-test-volume-for-third-quarter-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"bioAffinity Technologies Reports Record Growth in CyPath\u00ae Lung Test Volume for Third Quarter 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/893152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=893152"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/893152\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=893152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=893152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=893152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}